Breaking News, Financial News

Johnson & Johnson 1Q Results

Innovative Medicine sales were up 1%, while COVID-19 Vaccine sales were down 97%.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson 1Q Revenues: $21.4 billion (+2%) 1Q Earnings: $5.4 billion (loss of $491 million 1Q23) Comments: Innovative Medicine sales were up 1% to $13.6 billion in the quarter. DARZALEX (daratumumab) sales were $2.7 billion, up 19%. ERLEADA (apalutamide) sales were $689 million, up 27%. CARVYKTI (ciltacabtagene autoleucel) sales were $157 million, up from $72 million in 1Q23. TECVAYLI (teclistamab-cqyv) sales were $133 million, up from 63 million in 1Q23. Other Oncology sales were...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters